dimethyl-[2-(2-methylpyridin-4-yl)vinyl]amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: dimethyl-[2-(2-methylpyridin-4-yl)vinyl]amine
• 英文别名: dimethyl-[2-(2-methyl-pyridin-4-yl)-vinyl]-amine；N,N-Dimethyl-2-(2-methyl-4-pyridyl)ethenamine；(E)-N,N-dimethyl-2-(2-methylpyridin-4-yl)ethenamine
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: ABQJPDCATHYDEM-FNORWQNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  16.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  dimethyl-[2-(2-methylpyridin-4-yl)vinyl]amine 在 sodium periodate 作用下， 以 甲醇 为溶剂， 生成 2-甲基-4-吡啶甲醛
  参考文献：
  名称：

  Regioselective Hydroxylation of 2,4-Lutidine: A Practical Synthesis of 4-Hydroxymethyl-2-methylpyridine

  摘要：

  我们开发了一种实用的 4-hydroxymethyl-2-methylpyridine 合成方法，它利用 Evans 对现成的 2,4-lutidine 进行区域选择性石化作用，并用二甲基甲酰胺进行捕集。

  DOI：

  10.1055/s-2002-20960
• 作为产物：
  描述：

  2,4-二甲基吡啶 、 N,N-二甲基甲酰胺 在 正丁基锂 、 二乙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 1.59h， 生成 dimethyl-[2-(2-methylpyridin-4-yl)vinyl]amine
  参考文献：
  名称：

  Regioselective Hydroxylation of 2,4-Lutidine: A Practical Synthesis of 4-Hydroxymethyl-2-methylpyridine

  摘要：

  我们开发了一种实用的 4-hydroxymethyl-2-methylpyridine 合成方法，它利用 Evans 对现成的 2,4-lutidine 进行区域选择性石化作用，并用二甲基甲酰胺进行捕集。

  DOI：

  10.1055/s-2002-20960

文献信息

• 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1424336A1

  公开（公告）日：2004-06-02

  This invention provides a compound represented by the formula (I) : wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  这项发明提供了一种由以下式（I）表示的化合物： 其中R1是氢原子、卤素原子、羟基、硝基、可选择具有卤素取代基的烷基、可选择具有取代基的烷氧基、酰基或氨基； R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡啶并嘧啶基、吲哚基、四氢喹啉基或噻唑基，每种基团可能具有取代基； n为1或2；或其盐。该发明提供了一种安全的药物，包括具有优异的凋亡抑制作用和MIF结合作用的式（I）化合物，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤病变、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等。
• [EN] BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS<br/>[FR] BENZIMIDAZOLES ET ANALOGUES ASSOCIÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2010003048A1

  公开（公告）日：2010-01-07

  Provided herein are sirtuin-modulating compounds of formula (II) The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了公式（II）的调节sirtuin的化合物。这些调节sirtuin的化合物可用于延长细胞的寿命，并用于治疗和/或预防各种疾病和紊乱，包括与衰老或压力有关的疾病或紊乱、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症、潮红以及那些会受益于增加线粒体活性的疾病或紊乱。还提供了包含调节sirtuin化合物与另一治疗剂结合的组合物。
• [EN] IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS<br/>[FR] IMIDAZOPYRIDINE ET ANALOGUES LIÉS EN TANT QUE MODULATEURS DE LA SIRTUINE
  申请人：SIRTRIS PHARMACEUTICALS INC

  公开号：WO2009146358A1

  公开（公告）日：2009-12-03

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新颖的调节sirtuin的化合物及其使用方法。这些调节sirtuin的化合物可用于增加细胞的寿命，并用于治疗和/或预防各种疾病和紊乱，包括与老化或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症、潮红以及需要增加线粒体活性的疾病或紊乱相关的疾病或紊乱。还提供了包含sirtuin调节化合物与另一种治疗剂组合的组合物。
• Process for the preparation of isonicotinic acid derivatives
  申请人：Spurr Paul

  公开号：US20060100440A1

  公开（公告）日：2006-05-11

  The present invention relates to a process for the manufacture of compounds of formula Ia or Ib and pharmaceutically acceptable additional salts thereof, wherein R is lower alkyl. The compounds of formula Ia or Ib are valuable intermediate products for the manufacture of compounds that are pharmaceutically active as adenosine A2a receptor antagonist or metabotropic Glutamate receptor 2 antagonist. Such compounds are important in the regulation of many aspects of cellular metabolism and in the modulation of different central nervous system activities.

  本发明涉及一种制备化合物Ia或Ib及其药学上可接受的附加盐的方法，其中R为较低的烷基。化合物Ia或Ib的制备是制备具有药理活性的化合物的有价值的中间产物，这些化合物作为腺苷A2a受体拮抗剂或代谢型谷氨酸受体2拮抗剂具有药理活性。这些化合物在调节细胞代谢的许多方面以及调节不同中枢神经系统活动中起重要作用。
• 1, 3-benzothiazinone derivatives and use thereof
  申请人：Kajino Masahiro

  公开号：US20050032786A1

  公开（公告）日：2005-02-10

  This invention provides a compound represented by the formula (I): wherein R 1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R 2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  该发明提供了一个由式(I)表示的化合物：其中R1是氢原子、卤素原子、羟基、硝基、可选取代卤代烷基、可选取代基的烷氧基、酰基或氨基；R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡嗪啉基、吲哚基、四氢喹啉基或噻唑基，每个基团都可以有取代基；n为1或2；或其盐。该发明提供了一种安全的药物，包括式(I)化合物，具有出色的抑制细胞凋亡和结合MIF的效果，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤性疾病、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等疾病。